On August 28, Alnylam Pharmaceuticals fell 5.65% in pre-market trading, trading at $223.2 USD/share, with Turnover of $253,900.
Within the Biotechnology sector where Alnylam Pharmaceuticals belongs, the overall sector showed mixed performance. Among individual stocks, Moderna up 1.44%, AbbVie up 0.12%, Amgen up 0.69%, Gilead Sciences up 0.56%, Revolution Medicines up 0.70%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)